MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Acetylcholine"

  • 2023 International Congress

    Free water imaging of the cholinergic forebrain in body vs. brain-first Parkinson’s disease subtypes

    S. Roytman, Y. Ota, T. Brown, P. Scott, R. Albin, P. Kanel, N. Bohnen (Ann Arbor, USA)

    Objective: To investigate the relationship between basal forebrain (BF) neurodegeneration and cholinergic system in body vs brain-first Parkinson’s disease (PD) subtypes. Background: Free water imaging…
  • 2023 International Congress

    The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson’s disease

    S. Madiha (Karachi, Pakistan)

    Objective: The aim of the study was to compare the effects of curcumin and naringenin on rotenone-induced motor deficits and related neurochemical changes. Background: Experimental…
  • 2023 International Congress

    The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening

    C. Panteghini, C. Reale, I. Colangelo, M. Suerz, R. Cilia, R. Eleopra, B. Garavaglia, F. Invernizzi (Milano, Italy)

    Objective: Our aim is to offer a complete and reliable diagnostic service excluding false negative. Background: Heterozygous variants in the GBA gene are the most…
  • 2022 International Congress

    Muscarinic M2 cholinergic receptors in cervical dystonia

    P. Kassavetis, M. Hosseini, K. Mente, R. Waugh, E. Shamim, W. Dieckmann, P. Herscovitch, M. Hallett, S. Horovitz (Salt Lake City, USA)

    Objective: To characterize the M2 muscarinic acetylcholine receptor binding in patients with cervical dystonia, measured with non-invasive high-resolution PET, using [18F]FP-TZTP ligand. Background: While antimuscarinic…
  • 2022 International Congress

    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in REM Sleep Behavior Disorder

    C. Tan, H. Nawaz, S. Lageman, B. Berman, N. Mukhopadhyay, M. Barrett (Richmond, USA)

    Objective: To determine if there is evidence of cholinergic basal forebrain degeneration, i.e., reduced cholinergic nucleus 4 (Ch4) volume on MRI, in patients with REM…
  • 2022 International Congress

    Exploring the impact of central cholinergic dysfunction on cognitive functioning in patients of Parkinson’s disease with and without REM sleep behavior disorder

    A. Bhattacharya, K. Udupa, N. Kamble, M. Gothwal, S. Hegde, R. Yadav, PK. Pal (Bengaluru, India)

    Objective: This paper aims at establishes the presence of significantly higher cholinergic dysfunction in patients using short latency afferent inhibition. Background: Parkinson's disease (PD) is…
  • 2022 International Congress

    Relationship between cholinergic basal forebrain volume and short-latency sensory afferent inhibition in Parkinson’s disease with varying degrees of cognitive performance

    JF. Martín-Rodríguez, P. Franco Rosado, E. Iglesias Camacho, AM. Castellano-Gerrero, MA. Labrador-Espinosa, B. Villarreal, L. Muñoz-Delgado, D. Macías-García, P. álvarez Toledo, M. San Eufrasio, M. Reina Castillo, S. Jesús, A. Adarmes-Gómez, F. Carrillo, MJ. Grothe, P. Mir (Sevilla, Spain)

    Objective: To assess the relationship between volumetric measures of cholinergic basal forebrain (CBF) degeneration and short-latency sensory afferent inhibition (SAI) in Parkinson’s disease (PD). Background:…
  • 2022 International Congress

    Short-latency afferent inhibition for the assessment of cholinergic degeneration in Parkinson’s disease

    E. D'Angremont, I. Zijdewind, S. Vander Zee, E. de Vries, T. van Laar, I. Sommer (Groningen, Netherlands)

    Objective: Our objective is to assess how well short-latency afferent inhibition (SAI) represents cortical cholinergic system integrity in patients with Parkinson’s disease (PD), using cholinergic…
  • 2022 International Congress

    Parkinson’s disease and nucleus basalis of Meynert integrity: Cognition and everyday function

    N. Slater, R. Shoorangiz, G. Hall-Mcmaster, A. Harris, L. Livingston, S. Grenfell, K. Clifford, T. Anderson, T. Melzer, J. Dalrymle-Alford (Christchurch, New Zealand)

    Objective: To examine the association between the integrity of the nucleus basalis of Meynert (NBM), cognition and everyday function in Parkinson’s disease (PD). Background: Most…
  • 2022 International Congress

    The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different motor subtypes

    M. Nazmuddin, P. Zeidman, T. van Laar (Surabaya, Indonesia)

    Objective: We aim to compare the state of cortical-NBM functional connectivity across healthy control (HC), PIGD-predominant PD (PIGD-PD), and tremor-dominant PD (TD-PD). Additionally, the correlation…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley